NAD+ sits at the centre of cellular energy metabolism, and the question researchers actually care about \u2014 can raising it change something measurable in humans \u2014 now has randomized-trial answers.<\/p>\n
NAD+ is the coenzyme every cell uses to shuttle electrons during energy production, and it doubles as the fuel for sirtuins and DNA-repair enzymes. Its decline with age is one of the most replicated observations in ageing biology \u2014 which is why restoring it became a serious research field rather than a supplement fad.<\/p>\n
Peripheral artery disease restricts blood flow to the legs, and walking distance is the hard, functional endpoint trials use. In the NICE trial, participants randomized to nicotinamide riboside walked 31.0 metres farther in six minutes than the placebo group by the end of the study \u2014 a meaningful difference on an endpoint that does not respond to placebo effects easily. The authors call for a larger confirmatory trial, which is under way in the field.<\/p>\n
The randomized data is built on oral NAD+ precursors \u2014 molecules the body converts into NAD+. Research on NAD+ itself, including the vial format in this catalogue, sits alongside that literature: same target molecule, different route into the pathway. Our NAD+ explainer<\/a> covers what the molecule is and how its documentation works.<\/p>\n Yes. In the randomized NICE trial, the NAD+ precursor nicotinamide riboside improved six-minute walk distance by 31 metres versus placebo in peripheral artery disease.<\/p>\n Multiple randomized trials consistently show oral precursors raise blood NAD+ levels.<\/p>\nFrequently asked questions<\/h2>\n
Has raising NAD+ shown functional effects in trials?<\/h3>\n
Do oral NAD+ precursors actually raise NAD+ levels?<\/h3>\n